The IL3 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human MCF-7 breast adenocarcinoma cell line, engineered to disrupt the IL3 gene. This product provides a heterogeneous pool of knockout cells, enabling loss-of-function studies of interleukin-3 (IL-3) in a non-hematopoietic epithelial context. The CRISPR/Cas9-mediated gene disruption targets the IL3 locus, abolishing functional IL-3 cytokine production without introducing a specific clonal genotype, thereby facilitating population-level analyses.
The MCF-7 host cell line is an estrogen receptor-positive epithelial breast adenocarcinoma model derived from a pleural effusion of a 69-year-old female with metastatic disease. Widely used in cancer research, MCF-7 is instrumental for studying hormone-responsive pathways, drug sensitivity, and tumor biology. Although not a hematopoietic cell, its epithelial background and well-characterized signaling networks provide a valuable platform to investigate ectopic or paracrine IL-3 effects in the tumor microenvironment.
Interleukin-3 (IL-3) is a cytokine that stimulates hematopoietic cell proliferation and differentiation. It signals via IL3RA and CSF2RB, activating JAK2. Downstream, STAT5 is phosphorylated, along with PI3K/AKT and MAPK/ERK cascades, leading to expression of Bcl-xL and Cyclin D2. In immune cells, IL3 is regulated by T-cell receptor signaling, NFAT, AP-1, and pro-inflammatory cytokines like IL-1 and TNF. IL3 knockout disrupts these pathways, diminishing survival and proliferation signals.
In the MCF-7 background, IL3 knockout creates a model to dissect non-canonical roles of IL-3. Although MCF-7 is not a traditional IL-3 target, it may respond to paracrine IL-3 from the tumor microenvironment or upon ectopic expression. Eliminating endogenous IL-3 production permits study of how IL-3-mediated autocrine/paracrine loops influence proliferation, apoptosis, and signaling cross-talk in breast cancer cells, potentially revealing novel dependencies.
Researchers can use Western blotting to assess changes in downstream effectors such as phospho-STAT5, phospho-AKT, and phospho-ERK; RT-qPCR to quantify transcriptional alterations of IL-3-responsive genes; and ELISA to verify loss of secreted IL-3. Functional proliferation and apoptosis assays enable direct evaluation of IL-3-dependent growth or survival. These cells are also well-suited for co-culture experiments exploring paracrine crosstalk and for drug screening against IL-3 pathway components. For further technical details, please contact Ascent Research.
